Sotera Health Co

Sotera Health Co(SHC)股票分析

$17.890

-0.179 (-1.00%)收盘时

Loading chart…
最高
18.520
开盘
18.130
成交量加权均价
18.07
成交量
1.86M
市值
3.37B
最低
17.790
成交额
33.53M
企业价值/息税折旧摊销前利润(TTM)
11.13

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

AI 分析 of Sotera Health Co (SHC)

买入

Sotera Health Co (SHC) is a good buy right now, trading at $18.06 with a forward P/E of 17.76, which is attractive compared to its growth potential. The company has shown significant revenue growth, reporting Q2 revenue of $321.4 million, a 9.2% year-on-year increase, exceeding expectations. However, the main risk is its organic revenue growth weakness, averaging only 4.9% year-on-year, which may limit future performance.

估值指标

Sotera Health Co(SHC)当前预期市盈率为 17.76,5 年平均预期市盈率为 18.02。

预期市盈率

合理
5 年均值 P/E
18.02
当前P/E
17.76
高估
21.73
低估
14.31

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
11.45
当前EV/EBITDA
11.13
高估
13.65
低估
9.25

预期市销率

合理
5 年均值 P/S
3.96
当前P/S
3.83
高估
5.09
低估
2.83

Alphio AI 对 SHC 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%SHC

$12.30

情景价格

基

基准

基准 · 50%SHC

$11.71

情景价格

悲

悲观

悲观 · 25%SHC

$10.60

情景价格

持有 SHC 的大户

L

Lakewood Capital Management, LP

+ 持有SHC

+7.00%

3个月收益率

S

Sculptor Capital Management, Inc.

+ 持有SHC

-2.50%

3个月收益率

V

Voss Capital, LP

+ 持有SHC

-3.81%

3个月收益率

A

Ancora Advisors LLC

+ 持有SHC

-5.12%

3个月收益率

G

Greenlight Capital, Inc.

+ 持有SHC

-6.31%

3个月收益率

T

Two Seas Capital LP

+ 持有SHC

-8.89%

3个月收益率

事件时间线

2026-08-06 (ET)

07:30:00

Consensus Raises FY26 Revenue Outlook to $1.24B

07:30:00

Sotera Health Q2 Revenue Reaches $321.38M, Exceeds Expectations

2026-05-12 (ET)

09:30:00

Goldman Sachs Sole Bookrunner, Deal Range $15.27-$15.43

2026-05-11 (ET)

17:30:00

Goldman Sachs Acts as Sole Book Running Manager for Offering

16:40:00

Sotera Health Company Launches Secondary Offering of 31.84M Shares

资讯

SHC 常见问题 —— 由 Alphio AI 解答

Sotera Health Company is a global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. The Company's segments include Sterigenics, Nordion and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three technologies: gamma irradiation, ethylene oxide (EO) processing and E-beam irradiation. Nordion business is a global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a global provider of gamma irradiation systems. Its Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Sotera Health Co (SHC) is a good buy right now, trading at $18.06 with a forward P/E of 17.76, which is attractive compared to its growth potential. The company has shown significant revenue growth, reporting Q2 revenue of $321.4 million, a 9.2% year-on-year increase, exceeding expectations. However, the main risk is its organic revenue growth weakness, averaging only 4.9% year-on-year, which may limit future performance.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易